LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Editas Medicine Inc

Editas Medicine Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.76 3.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.73

Max

2.76

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-19M -25M
Pardavimai	-22M 2.8M
Pelnas, tenkantis vienai akcijai	-0.26
Pelno marža	-882.444
Darbuotojai	87
EBITDA	-19M -25M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+139.13% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-52M 241M
Ankstesnė atidarymo kaina	-0.61
Ankstesnė uždarymo kaina	2.76

Naujienos nuotaikos

By Acuity

50%

146 / 345 reitingas Healthcare

Editas Medicine Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-24 23:46; UTC

Rinkos pokalbiai

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

2026-05-24 23:45; UTC

Rinkos pokalbiai

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-24 23:42; UTC

Rinkos pokalbiai

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

2026-05-24 23:34; UTC

Rinkos pokalbiai

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

2026-05-24 23:11; UTC

Rinkos pokalbiai

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

2026-05-24 22:26; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

2026-05-24 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

2026-05-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

2026-05-24 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

2026-05-24 22:11; UTC

Rinkos pokalbiai

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

2026-05-24 22:04; UTC

Rinkos pokalbiai

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-23 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Akcijų palyginimas

Kainos pokytis

Editas Medicine Inc Prognozė

Kainos tikslas

By TipRanks

139.13% į viršų

12 mėnesių prognozė

Vidutinis 6.6 USD 139.13%

Aukščiausias 15 USD

Žemiausias 4 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Editas Medicine Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Editas Medicine Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

146 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.